Sign in Subscribe
Vaccination

United States Vaccine Market to Reach $11.4 Billion by 2026

Strategic Insights

— 2 min read

The United States vaccine market has undergone significant growth, largely due to the increasing awareness of vaccination and government initiatives. The market is expected to continue its upward trend, reaching $11.4 billion by 2026. Vaccines have played a crucial role in transforming public health worldwide, especially for children. In the United States, among the various diseases targeted by vaccines, influenza is the most common viral infection, with quadrivalent flu vaccine being the most common.

Influenza can affect anyone at any time, but it typically spreads between May and October. To increase awareness and importance of vaccination, the National Immunization Awareness Day is celebrated in August. These immunization awareness and government initiatives have helped prevent 2-3 million deaths annually, according to the World Health Organisation. The simplicity, power, and cost-effectiveness of vaccines make them a vital health intervention.

Key Takeaways:

  • The United States vaccine market is expected to reach $11.4 billion by 2026, according to the publisher.
  • Quadrivalent flu vaccine is the most common vaccine in the United States, licensed in 2012.
  • Influenza is the most common viral infection in the United States, typical spreading from May to October.
  • The National Immunization Awareness Day is celebrated in August to increase awareness and importance of vaccination.
  • Immunization awareness and government initiatives have helped prevent 2-3 million deaths annually, according to the World Health Organisation.
  • All 10 vaccines have been studied from three points: Vaccines Market, Immunized Population (Infants), and Doses of Vaccines Administered.
  • The company analysis has been covered from four viewpoints: Overview, Recent Developments, Revenue Analysis, and Vaccinations Pipeline & Clinical Trials.
  • Key players in the vaccine market include GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur, and Pfizer, Inc.
  • Top players in the vaccine market have experienced significant sales growth, with GlaxoSmithKline, plc, reporting $10.3 billion in sales, Merck & Co, $9.5 billion, Sanofi Pasteur, $8.2 billion, and Pfizer, Inc., $7.1 billion.

Statistics:

  • 2-3 million deaths annually prevented by immunization awareness and government initiatives (World Health Organisation).
  • Influenza vaccine market size expected to grow to $11.4 billion by 2026.
  • Quadrivalent flu vaccine licensed in 2012.
  • Average human life span increased significantly due to vaccination.
  • Number of vaccinated infants: Influenza (30.3%), Hepatitis B (95.1%), Hepatitis A (91.2%), Polio (99.1%), DTaP (92.5%), HIB (89.4%), Pneumococcal conjugate (79.4%), Varicella (79.4%), MMR (85.6%), and HPV (52.4%).

Sources:

  • "United States Vaccine Market By Type (Influenza, Retrovirus, Hepatitis, Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV), Products and Pipeline, Companies" report, ResearchAndMarkets.com.
  • World Health Organisation (no specific date or publication).
  • M2 Communications, M2 PressWIRE (December 10, 2020).

Read more